Unilever PLC: Q3 2024 Trading Statement Summary
Business Context and Reporting Period
This Form 6-K filing, dated October 24, 2024, reports Unilever PLC's unaudited trading results for the third quarter and nine months ended September 30, 2024. The company is a global consumer goods manufacturer operating across Beauty & Wellbeing, Personal Care, Home Care, Nutrition, and Ice Cream business groups. The reporting period highlights the execution of the "Growth Action Plan," a productivity programme, and the ongoing separation of the Ice Cream business.
Key Financial Metrics
Revenue and Growth (Q3 2024):
- Turnover: €15.2 billion (flat vs. prior year).
- Underlying Sales Growth (USG): 4.5%.
- Underlying Volume Growth (UVG): 3.6% (fourth consecutive quarter of positive growth).
- Underlying Price Growth (UPG): 0.9% (moderating as expected).
- Currency Impact: (2.8)% negative impact.
- Disposals Impact: (1.5)% negative impact.
Profitability and Margins:
- Full Year 2024 Outlook: Underlying operating margin expected to be at least 18%.
- Margin Progression: Expected to be smaller in the second half of the year compared to the first half due to increased brand investment.
Cash Flow and Capital Allocation:
- Share Buyback: Final tranche of the €1.5 billion 2024 programme is underway (second tranche of up to €800 million commenced in September).
- Dividend: Q3 2024 interim dividend maintained at €0.4396 per ordinary share.
- Divestitures: Completed sale of Russian subsidiary to Arnest Group (Oct 10) and stake in Qinyuan Group (Truliva) to Yong Chao Venture Capital (Aug 2).
Material Changes vs. Prior Period
Volume-Led Recovery: The company reported volume growth of 3.6% in Q3, an improvement from 2.9% in the first nine months and a reversal of prior volume declines. All five business groups achieved positive volume growth.
Business Group Performance:
- Beauty & Wellbeing: Strongest performer with 6.7% USG, driven by 5.7% volume growth (led by Health & Wellbeing and Prestige Beauty).
- Ice Cream: Highest growth at 9.8% USG (6.7% volume), aided by a weak prior-year comparator and operational improvements.
- Personal Care: 4.4% USG driven by Dove performance.
- Home Care: 1.9% USG; volume growth of 3.3% was offset by negative price growth of (1.4)% due to commodity deflation.
- Nutrition: Modest 1.5% USG with muted volume growth (0.4%).
Geographical Shifts: Developed markets grew 6.9% USG, while Emerging markets grew 2.9% USG. Significant declines were noted in Indonesia ((18)% USG) and China (low-single digit decline) due to operational challenges and market weakness.
Guidance, Outlook, and Risks
Outlook: The full-year 2024 outlook remains unchanged. Unilever expects USG of 3-5% and an underlying operating margin of at least 18%.
Strategic Initiatives:
- Ice Cream Separation: On track to complete by end of 2025; legal entity setup and carve-out financials are progressing.
- Productivity Programme: Implementation has begun in countries where works council consultations are complete.
- Market Interventions: Decisive actions are being taken in Indonesia (price stability, stock resets) and China (go-to-market transformation), with benefits expected in H2 2025.
Risks and Contingencies:
- Execution Risk: Success of the Ice Cream separation and productivity programme.
- Market Volatility: Continued weakness in China and operational issues in Indonesia.
- External Factors: Commodity cost volatility, supply chain disruptions, and hyperinflationary pricing in certain markets.
Investor Verification Checklist
- Verify the sustainability of volume growth (3.6%) across all business groups in Q4 to confirm the trend.
- Monitor the execution timeline and cost savings realization of the productivity programme.
- Track the progress of the Ice Cream separation and the impact on operational synergies.
- Assess the turnaround trajectory in Indonesia and China, specifically looking for signs of stabilization in H1 2025.
- Confirm the completion of the €1.5 billion share buyback programme by December 2024.
- Review the impact of negative price growth in Home Care on overall margin targets.